About us

Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company's latest innovations include a unique, full automation system, the industry's most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.

At Diagenode, our goal is to build products with pride and the highest level of performance. Our team of epigenetics experts develop products by getting feedback from our customers as well as the scientific and medical communities around us. We strive to develop superior and easy-to-use products to bring epigenetics research and diagnostics to new frontiers.

Diagenode specializes in serving two fast growing markets

Epigenetics research

Epigenetics is playing a revolutionary role in life sciences research. Diagenode continually innovates solutions and provides the highest quality epigenetics tools available.

  • Bioruptor DNA and Chromatin shearing

  • Automation - ChIP, DNA methylation, NGS library prep

  • Validated ChIP, DNA methylation and NGS library prep solutions

  • Ultra-validated ChIP antibodies

Molecular Diagnostics

Diagenode offers amplification and quantification methods for DNA targets of human infectious disease to meet the fast-paced growth of human disease diagnostics. We also provide guidance to diagnostics companies to develop epigenetics-based diagnostics. Our products are designed to make diagnostic assays simpler, faster, and of highest quality. Our kits are CE-marked and certified ISO 9001 and ISO 13485.

For more information about our company, please contact us:


 See all events

Twitter feed


 See all news